Oxaliplatin induces mitotic catastrophe and apoptosis in esophageal cancer cells

Cancer Science

Volumn 99, Issue 1, 2008, Pages 129-139

  Ngan, Chew Yee ^a   Yamamoto, Hirofumi ^a   Takagi, Akimitsu ^b   Fujie, Yujiro ^a   Takemasa, Ichiro ^a   Ikeda, Masataka ^a   Takahashi Yanaga, Fumi ^c   Sasaguri, Toshiyuki ^c   Sekimoto, Mitsugu ^a   Matsuura, Nariaki ^d   Monden, Morito ^a  

^a OSAKA UNIVERSITY   (Japan)

^b YAKULT CENTRAL INSTITUTE FOR MICROBIOLOGICAL RESEARCH   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA A KINASE; AURORA B KINASE; CASPASE; CISPLATIN; CYTOCHROME C; OXALIPLATIN; PROTEASOME; PROTEIN 14 3 3; PROTEIN BAD; PROTEIN BID; PROTEIN NOXA; SMALL INTERFERING RNA; SURVIVIN; TRANSCRIPTION FACTOR SP1;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL DEATH; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG TARGETING; ENZYME RELEASE; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENE ACTIVITY; HUMAN; HUMAN CELL; IC 50; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MITOSIS INHIBITION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; STOMACH ADENOCARCINOMA; STRAIN DIFFERENCE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CISPLATIN; ESOPHAGEAL NEOPLASMS; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; MITOSIS; NEOPLASM PROTEINS; ORGANOPLATINUM COMPOUNDS; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; RNA, SMALL INTERFERING; SP1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR;

EID: 36949016065     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00637.x     Document Type: Article

References (44)

1. Rixe O, Ortuzar W, Alvarez M et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's anticancer drug screen panel. Biochem Pharmacol 1996; 52: 1855-65.
2. Woynarowski JM, Faivre S, Herzig MCS et al. Oxaliplatin-induced damage of cellular DNA. Mol Pharmacol 2000; 58: 920-7.
3. Tashiro T, Kawada Y, Sakurai Y, Kidani Y. Antitumor activity of a new platinum complex, oxalato (trans-1-1,2-diaminocyclohexane) platinum (II): New experimental data. Biomed Pharmacother 1989; 43: 251-60.
4. Scheeff ED, Briggs JM, Howell SB. Molecular modeling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin. Mol Pharmacol 1999; 56: 633-43.
5. Misset JL, Bleiberg H, Sutherland W, Bekradda M, Cvitkovic E. Oxaliplatin clinical activity: A review. Crit Rev Oncol Hematol 2000; 35: 75-93.
6. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
7. Khushalani NI, Leichman CG, Proulx G et al. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: Report of a clinical trial for patients with esophageal cancer. J Clin Oncol 2002; 20: 2844-50.
8. Maurel J, Cervantes A, Conill C et al. Phase I trial of oxaliplatin in combination with cisplatin, protracted-infusion fluorouracil, and radiotherapy in advanced esophageal and gastroesophageal carcinoma. Int J Radiat Oncol Biol Phys 2005; 62: 91-6.
9. Hata T, Yamamoto H, Ngan CY et al. Role of p21 waf1/cip1 in effects of oxaliplatin in colorectal cancer cells. Mol Cancer Ther 2005; 4: 1585-94.
10. Arango D, Wilson AJ, Shi Q et al. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer 2004; 91: 1931-46.
11. Wang X, Li M, Wang J et al. The BH3-only protein, PUMA, is involved in oxaliplatin-induced apoptosis in colon cancer cells. Biochem Pharmacol 2006; 71: 1540-50.
12. Hayward RL, MacPherson JS, Cummings J, Monia BP, Smyth JF, Jodrell DI. Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect. Mol Cancer Ther 2004; 3: 169-78.
13. Nishihira T, Hashimoto Y, Katayama M, Mori S, Kuroki T. Molecular and cellular features of esophageal cancer cells. J Cancer Res Clin Oncol 1993; 119: 441-9.
14. Fujie Y, Yamamoto H, Ngan CY et al. Oxaliplatin, a potent inhibitor of survivin, enhances paclitaxel-induced apoptosis and mitotic catastrophe in colon cancer cells. Jpn J Clin Oncol 2005; 35: 453-63.
15. Lock RB, Stribinskiene L. Dual modes of death induced by etoposide in human epithelial tumor cells allow bcl-2 to inhibit apoptosis without affecting clonogenic survival. Cancer Res 1996; 56: 4006-12.
16. Yamamoto H, Kondo M, Nakamori S et al. JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis. Gastroenterol 2003; 125: 556-71.
17. Hayashi N, Yamamoto H, Hiraoka N et al. Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm. Hepatology 2001; 34: 638-50.
18. Williams NS, Gaynor RB, Scoggin S et al. Idenfication and validation of genes involved in the pathogenesis of colorectal cacner using cDNA microarrays and RNA interference. Clin Cancer Res 2003; 9: 931-46.
19. Sakoguchi-Okada N, Takahashi-Yanaga F, Fukada K et al. Celecoxib inhibits the expression of survivin via the suppression of promoter activity in human colon cancer cells. Biochem Pharmacol 2007; 73: 1318-29.
20. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 2004; 4: 592-603.
21. Gu J, Yamamoto H, Lu X et al. Low-dose oxaliplatin enhances the antitumor efficacy of paclitaxel in human gastric cancer cell lines. Digestion 2006; 74: 19-27.
22. Blot WJ. Esophageal cancer trends and risk factors. Semin Oncol 1994; 21: 403-10.
23. Stergiou L, Hengartner MO. Death and more: DNA damage response pathways in the nematode C. elegans. Cell Death Diff 2004; 11: 21-8.
24. van Vugt MA, Bras A, Medema RH. Restarting the cell cycle when the checkpoint comes to a halt. Cancer Res 2005; 65: 7037-40.
25. Lock RB, Galperina OV, Feldhoff RC, Rhodes LJ. Concentration-dependent differences in the mechanisms by which caffeine potentiates etoposide cytotoxicity in HeLa cells. Cancer Res 1994; 54: 4933-9.
26. Ruth AC, Roninson IB. Effects of the multidrug transporter P-glycoprotein on cellular responses to ionizing radiation. Cancer Res 2000; 60: 2576-8.
27. Tounekti O, Pron G, Belehradek J, Mir LM. Bleomycin, an apoptosis-mimetic drug that induces two types of cell death depending on the number of molecules internalized. Cancer Res 1993; 53: 5462-9.
28. Magalska A, Sliwinska M, Szczepanowska J, Salvioli S, Franceschi C, Sikora E. Resistance to apoptosis of HCW-2 cells can be overcome by curcumin- or vincristine-induced mitotic catastrophe. Int J Cancer 2006; 119: 1811-18.
29. Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B. 14-3-3σ is required to prevent mitotic catastrophe after DNA damage. Nature 1999; 401: 616-20.
30. Li F, Ambrosini G, Chu EY et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998; 396: 580-4.
31. Mantel C, Braun SE, Reid S et al. p21 waf1/cip1 deficiency causes deformed nuclear architecture, centriole overduplication, polyploidy, and relaxed microtubule damage checkpoints in human hematopoietic cells. Blood 1999; 93: 1390-8.
32. Scaife RM. G2 cell cycle arrest, down-regulation of cyclin B, and induction of mitotic catastrophe by the flavoprotein inhibitor diphenyleneiodonium. Mol Cancer Ther 2004; 3: 1229-37.
33. Tarnawski A, Pai R, Chiou S-K, Chai J, Chu EC. Rebamipide inhibits gastric cancer growth by targeting survivin and Aurora-B. Biochem Biophys Res Comm 2005; 334: 207-12.
34. Kato J, Kuwabara Y, Mitani M et al. Expression of survivin in esophageal cancer: Correlation with the prognosis and response to chemotherapy. Int J Cancer 2001; 95: 92-5.
35. Nemoto T, Kitagawa M, Hasegawa M et al. Expression of IAP family proteins in esophageal cancer. Exp Mol Pathol 2004; 76: 253-9.
36. Li F, Ackermann EJ, Bennett F et al. Pleitropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1999; 1: 461-6.
37. Yang D, Welm A, Bishop JM. Cell division and cell survival in the absence of survivin. Proc Natl Acad Sci USA 2004; 101: 15.100-5.
38. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-21.
39. Kobayashi K, Hatano M, Otaki M et al. Expression of a murine homologue of the inhibitor of apoptosis protein is related to cell proliferation. Proc Natl Acad Sci USA 1999; 96: 1457-62.
40. Gritsko T, Williams A, Turkson J et al. Persistent activation of Stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 2006; 12: 11-19.
41. Hsieh F-C, Cheng G, Lin J. Evaluation of potential Stat3-regulated genes in human breast cancer. Biochem Biophys Res Comm 2005; 335: 292-9.
42. Li F, Altieri DC. Transcriptional analysis of human survivin gene expression. Biochem J 1999; 344: 305-11.
43. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3: 46-54.
44. Ehrsson H, Wallin I, Yachnin J. Pharmacokinetics of oxaliplatin in humans. Med Oncol 2002; 19: 261-5.